June 9, 2020, Vol 323, No. 22, Pages 2231-2350
Emergency Use Authorization of Remdesivir- The Need for a Transparent Distribution Process
Michael G. Ison, MD, MS; Cameron Wolfe, MBBS, MPH; Helen W. Boucher, MD
JAMA. 2020;323(23):2365-2366. doi:10.1001/jama.2020.8863
This Viewpoint reviews the FDA’s May 2020 Emergency Use Authorization of the antiviral drug remdesivir for treatment of COVID-19 and discusses the need for a transparent distribution plan of a drug not otherwise available in the US and for which demand will likely exceed supply.